Lack of state funding and understaffing are threatening the vaccination campaign for novel Omicron-specific booster shots; experts explore the differences between subcutaneous and intradermal delivery of monkeypox vaccines; HHS’ Office for Civil Rights is struggling to manage rising cases of cyberattacks on US health care organizations.
As the United States prepares to launch a campaign this fall aimed at distributing novel Omicron-specific booster shots, The New York Times is reporting that a lack of state funding and understaffed or eliminated local programs that previously delivered the shots may impede access for Americans. Weak demand for vaccines and better survival rates of COVID-19 were cited by some state health officials as reasoning behind the reduction in funding toward COVID-19 vaccine delivery efforts, and increased attention toward the monkeypox outbreak and childhood immunization deficits were also noteworthy.
The Washington Post reviewed differences between subcutaneous and intradermal vaccine delivery, with the latter recently approved by the FDA as a dose-sparing approach that increases monkeypox vaccine supply. Allowing health care providers to use an existing 1-dose vial of the vaccine to administer a total of up to 5 separate doses intradermally, as opposed to subcutaneously, the approach was indicated to require considerable skill and training as it is rarely used for vaccinations. One key benefit of intradermal delivery is that it is absorbed much faster and may elicit a higher immune response, and therefore would require potentially less vaccine to achieve the same result as a subcutaneous vaccination.
Amid rising cases of cyberattacks among US health care organizations, POLITICO is reporting that HHS’ Office for Civil Rights, which is assigned to investigate breaches and help health systems bolster their defenses, is poorly positioned to help due to inadequate budgeting and understaffing. Lack of cooperation from affected organizations is also an issue as they may be reluctant to report data breaches because of potential Health Insurance Portability and Accountability Act violations leading to fines from HHS that would compound onto costs stemming from the breach and the ransoms potentially demanded by the hackers. A total of 113 million people have been affected by health care data breaches of US health care organizations, with 53,000 cases expected to come in the 2022 fiscal year.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More